ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Chaihu Shugan powder alleviates liver inflammation and hepatic steatosis in NAFLD mice: A network pharmacology study and in vivo experimental validation

Lei, Sisi; Zhao, Shuai; Huang, Xiaoyan; Feng, Yuchao; Li, Zhishang; Chen, Li; Huang, Peiying; Guan, Hansu; Zhang, Haobo; Wu, Qihua; Chen, Bojun*广州中医药大学
Frontiers in Pharmacology2022-9-12DOI: 10.3389/fphar.2022.967623
3被引19阅读
引用收藏
分享

摘要

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common metabolic disease and is intertwined with cardiovascular disorders and diabetes. Chaihu Shugan powder (CSP) is a traditional Chinese medicine with a significant therapeutic effect on metabolic diseases, such as NAFLD. However, its pharmacological mechanisms remain to be elucidated. Methods: The main compounds of CSP were measured using LC-MS/MS. A network pharmacology study was conducted on CSP. Its potential active ingredients were selected according to oral bioavailability, drug similarity indices, and phytochemical analysis. After obtaining the intersected genes between drug targets and disease-related targets, the component-disease-target network and protein-protein interaction analysis were visualized in Cytoscape. GO and KEGG enrichment analyses were performed using the Metascape database. Six-week-old male C57BL/6 mice fed a high-fat high-fructose diet for 16 weeks plus chronic immobilization stress for 2 weeks, an in vivo model, were administered CSP or saline intragastrically. Liver histology, triglyceride and cholesterol levels, ELISA, and RT-PCR were used to assess hepatic inflammation and steatosis. Immunohistochemistry and western blotting were performed to assess protein levels. Results: A total of 130 potential target genes in CSP that act on NAFLD were identified through network pharmacology assays, including tumor necrosis factor (TNF), interleukin-6 (IL6), interleukin-1 beta (IL-1 beta), and peroxisome proliferator-activated receptor gamma (PPARG). KEGG enrichment analysis showed that the main pathways were involved in inflammatory pathways, such as the TNF and NF-kappa B signaling pathways, and metabolism-related pathways, such as the MAPK, HIF-1, FoxO, and AMPK signaling pathways. The results in vivo showed that CSP ameliorated liver inflammation and inhibited hepatic fatty acid synthesis in the hepatocyte steatosis model. More specifically, CSP therapy significantly inhibited the expression of tumor necrosis factor alpha (TNF alpha), accompanied by a decrease in TNF receptor 1 (TNFR1) and the ligand availability of TNFR1. Conclusion: Through the combination of network pharmacology and in vivo validation, this study elucidated the therapeutic effect of CSP on NAFLD, decreasing liver inflammation and inhibiting hepatic fatty acid synthesis. More specifically, the anti-inflammatory action of CSP was at least partially mediated by inhibiting the TNF alpha/TNFR1 signaling pathway.

学科与关键词

关键词
chaihu shugan powdernonalcoholic fatty liver diseaseinflammationsystems pharmacologyfatty acid synthesisTNFa/TNFR1 pathway
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-09-12
卷期
第 13 卷
页码
967623
DOI
10.3389/fphar.2022.967623
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; [82004268]; [82074342]

作者

  • L

    Lei, Sisi (第一作者)

    2 · guangzhou univ chinese med

  • Z

    Zhao, Shuai

    2 · guangzhou univ chinese med

查看全部 11 位作者收起作者
  • H

    Huang, Xiaoyan

    2 · guangzhou univ chinese med

  • F

    Feng, Yuchao

    2 · guangzhou univ chinese med

  • L

    Li, Zhishang

    2 · guangzhou univ chinese med

  • C

    Chen, Li

    2 · guangzhou univ chinese med

  • H

    Huang, Peiying

    2 · guangzhou univ chinese med

  • G

    Guan, Hansu

    guangzhou univ chinese med

  • Z

    Zhang, Haobo

    2 · guangzhou univ chinese med

  • W

    Wu, Qihua

    2 · guangzhou univ chinese med

  • C

    Chen, Bojun (通讯)

    2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417